Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas

References

• Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589–1592. doi:10.1126/science.111206315947177
   PubMed Web of Science ®Google Scholar
• Tristan M, Orozco LJ, Steed A, Ramírez-Morera A, Stone P. Mifepristone for uterine fibroids. Cochrane Database Syst Rev. 2012;8(8):CD007687.22895965
   PubMed Web of Science ®Google Scholar
• Esteve CJL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas. Obstet Gynecol. 2008;112(5):1029–1036. doi:10.1097/AOG.0b013e31818aa93018978102
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009;146(2):215–218. doi:10.1016/j.ejogrb.2009.06.00419586708
   PubMed Web of Science ®Google Scholar
• Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril. 2013;100(6):1722–1726. doi:10.1016/j.fertnstert.2013.08.03924094421
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12(3):227–233. doi:10.1016/j.jmig.2005.01.02215922980
   PubMed Web of Science ®Google Scholar
• Kasprzak A, Kwasniewski W, Adamek A, Gozdzicka-Jozefiak A. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 2017;772:78–104. doi:10.1016/j.mrrev.2016.08.00728528692
   PubMed Web of Science ®Google Scholar
• Amutha P, Rajkumar T. Role of insulin-like growth factor, insulin-like growth factor receptors, and insulin-like growth factor-binding proteins in ovarian cancer. Indian J Med Paediatr Oncol. 2017;38(2):198–206. doi:10.4103/ijmpo.ijmpo_3_1728900330
   PubMed Web of Science ®Google Scholar
• Kwasniewski W, Gozdzicka-Jozefiak A, Kotarska M, et al. Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer. Mol Med Rep. 2015;11(2):766–774. doi:10.3892/mmr.2014.291625384883
   PubMed Web of Science ®Google Scholar
• Shafiee MN, Seedhouse C, Mongan N, et al. Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer. Mol Cell Endocrinol. 2016;424:94–101. doi:10.1016/j.mce.2016.01.01926802879
   PubMed Web of Science ®Google Scholar
• Baird DD, Travlos G, Wilson R, et al. Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. Epidemiology. 2009;20(4):604–610. doi:10.1097/EDE.0b013e31819d8d3f19305350
   PubMed Web of Science ®Google Scholar
• Shen Q, Hu X, Zhou L, Zou S, LZ S, Zhu X. Overexpression of the 14-3-3γ protein in uterine leiomyoma cells results in growth retardation and increased apoptosis. Cell Signal. 2018;45:43–53. doi:10.1016/j.cellsig.2018.01.02529382566
   PubMed Web of Science ®Google Scholar
• Luo X, Yin P, Reierstad S, et al. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab. 2009;94(11):4533–4539. doi:10.1210/jc.2009-128619808856
   PubMed Web of Science ®Google Scholar
• Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571–588. doi:10.1016/j.bpobgyn.2008.04.00218534913
   PubMed Web of Science ®Google Scholar
• McCarthy-Keith DM, Malik M, Britten J, Segars J, Catherino WH. Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells. Fertil Steril. 2011;95(7):2383–2387. doi:10.1016/j.fertnstert.2011.03.08421496801
   PubMed Web of Science ®Google Scholar
• Engman M, Varghese S, Robinson KL, et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One. 2013;8(12):e80114. doi:10.1371/journal.pone.008011424324590
   PubMed Web of Science ®Google Scholar
• Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med. 2014;20(1):202–214. doi:10.2119/molmed.2014.0001124637928
   PubMed Web of Science ®Google Scholar
• Eshet R, Gil-Ad I, Apelboym O, Segev Y, Phillip M, Werner H. Modulation of brain insulin-like growth factor I (IGF-I) binding sites and hypothalamic GHRH and somatostatin levels by exogenous growth hormone and IGF-I in juvenile rats. J Mol Neurosci. 2004;22(3):179–188. doi:10.1385/JMN:22:3:17914997011
   PubMed Web of Science ®Google Scholar
• Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol. 1996;14(3):269–282. doi:10.1055/s-2007-10163368885057
   PubMedGoogle Scholar
• Nierth-Simpson EN, Martin MM, Chiang TC, et al. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17 beta-estradiol signaling: implications for proliferation. Endocrinology. 2009;150(5):2436–2445. doi:10.1210/en.2008-022419179429
   PubMed Web of Science ®Google Scholar
• Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14(2):342–346. doi:10.1158/1078-0432.CCR-07-479018223206
   PubMed Web of Science ®Google Scholar
• Kohno M, Tanimura S, Ozaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull. 2011;34(12):1781–1784. doi:10.1248/bpb.34.178122130230
   PubMed Web of Science ®Google Scholar
• Ng SSM, Jorge S, Malik M, et al. A-Kinase Anchoring Protein 13 (AKAP13) augments progesterone signaling in uterine fibroid cells. J Clin Endocrinol Metab. 2019;104(3):970–980. doi:10.1210/jc.2018-0121630239831
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Dolmans MM. The current place of medical therapy in uterine fibroid management. Best Pract Res Clin Obstet Gynaecol. 2018;46:57–65. doi:10.1016/j.bpobgyn.2017.10.00829169896
   PubMed Web of Science ®Google Scholar
• Chegini N, Kornberg L. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig. 2003;10(1):21–26.
   PubMedGoogle Scholar
• Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247–253. doi:10.1016/j.fertnstert.2010.07.104120736132
   PubMed Web of Science ®Google Scholar
• Xu X, Lu Z, Qiang W, et al. Inactivation of AKT induces cellular senescence in uterine leiomyoma. Endocrinology. 2014;155(4):1510–1519. doi:10.1210/en.2013-192924476133
   PubMed Web of Science ®Google Scholar